NDAORALCAPSULE, TABLETPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA DUAL PAK is a fixed-dose combination of vonoprazan fumarate (a potassium-competitive acid blocker) and amoxicillin for oral administration. It is indicated for Helicobacter pylori eradication in adults. This dual-agent regimen targets acid suppression and bacterial elimination simultaneously.
Peak4.3 years to LOE
Product is in peak commercial phase post-2022 approval; commercial teams are likely scaling sales infrastructure and reimbursement strategies in a high-competitive market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOQUEZNA DUAL PAK at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.